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Abstract
Background: Type 1 diabetes (T1D) is a T-cell mediated autoimmune disease targeting the insulin-producing pancreatic b
cells. Naturally occurring FOXP3
+CD4
+CD25
high regulatory T cells (Tregs) play an important role in dominant tolerance,
suppressing autoreactive CD4
+ effector T cell activity. Previously, in both recent-onset T1D patients and b cell antibody-
positive at-risk individuals, we observed increased apoptosis and decreased function of polyclonal Tregs in the periphery. Our
objective here was to elucidate the genes and signaling pathways triggering apoptosis in Tregs from T1D subjects.
Principal Findings: Gene expression profiles of unstimulated Tregs from recent-onset T1D (n=12) and healthy control
subjects (n=15) were generated. Statistical analysis was performed using a Bayesian approach that is highly efficient in
determining differentially expressed genes with low number of replicate samples in each of the two phenotypic groups.
Microarray analysis showed that several cytokine/chemokine receptor genes, HLA genes, GIMAP family genes and cell
adhesion genes were downregulated in Tregs from T1D subjects, relative to control subjects. Several downstream target
genes of the AKT and p53 pathways were also upregulated in T1D subjects, relative to controls. Further, expression
signatures and increased apoptosis in Tregs from T1D subjects partially mirrored the response of healthy Tregs under
conditions of IL-2 deprivation. CD4
+ effector T-cells from T1D subjects showed a marked reduction in IL-2 secretion. This
could indicate that prior to and during the onset of disease, Tregs in T1D may be caught up in a relatively deficient cytokine
milieu.
Conclusions: In summary, expression signatures in Tregs from T1D subjects reflect a cellular response that leads to increased
sensitivity to apoptosis, partially due to cytokine deprivation. Further characterization of these signaling cascades should
enable the detection of genes that can be targeted for restoring Treg function in subjects predisposed to T1D.
Citation: Jailwala P, Waukau J, Glisic S, Jana S, Ehlenbach S, et al. (2009) Apoptosis of CD4
+CD25
high T Cells in Type 1 Diabetes May Be Partially Mediated by IL-2
Deprivation. PLoS ONE 4(8): e6527. doi:10.1371/journal.pone.0006527
Editor: Patrick Tan, Duke-NUS Graduate Medical School, Singapore
Received April 21, 2009; Accepted July 2, 2009; Published August 5, 2009
Copyright:  2009 Jailwala et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by General Clinical Research Center of The Medical College of Wisconsin, Grant M01-RR00058 and the McGee funds from the
Children’s Research Institute (#2750.615). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sghosh@mcw.edu
. These authors contributed equally to this work.
Introduction
Type 1 diabetes (T1D) results from the T-cell-mediated
autoimmune destruction of the insulin-producing pancreatic islet
b cells. This breakdown of immunological self-tolerance results in
autoreactivity to islet self-antigens, and requires genetic susceptibil-
ity as well as environmental factors. Both the numerical and
functional balance between killer (e.g., CD4
+ and CD8
+ effectors)
and regulatory T-cells in the pancreatic infiltrate determines the
extent of b cell destruction [1]. Although islet infiltrates have shown
the presence of cytotoxic effector T-cells and pro-inflammatory
cytokines [2], there is still a major void in our understanding of how
these effector cells escape peripheral regulation.
Among the regulatory T-cells that actively suppress effector T-
cells, the FOXP3
+CD4
+CD25
high T-cells (Tregs) represent one of
the best characterized sub-populations. There is accumulating
evidence of a deficiency in either the frequency or function of Tregs
in various human autoimmune diseases [3], as well as in the
pathogenesis of T1D [4–7]. During the period right after disease
onset, which lasts several months after clinical diagnosis, most
T1D patients have some residual b-cell function [8,9]. Our group
is interested to study immune responses in the periphery related to
b-cell destruction and progression of disease during this recent-
onset period. We previously reported evidence for increased
apoptosis of Tregs in recent-onset T1D subjects (all diagnosed
within 1 year, henceforth referred to as ‘‘T1D subjects’’) and in
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found to correlate with a decline in suppressive potential of these
cells. The fact that both hyperglycemic T1D subjects and
normoglycemic at-risk subjects showed this phenomenon suggests
that Treg apoptosis is more a precursor to, rather than a
consequence of diabetes. Although Treg apoptosis is likely to be
one of the peripheral imbalances in T1D, there is very little known
about the pathways and genes that make Tregs sensitive to
apoptosis during the period right after the onset of disease.
Several groups have studied expression profiles for various
subsets of T-cells in both humans and mice, aimed at objectives
ranging from differentiating regulatory T-cells from effector T-
cells [11,12] to understanding the FOXP3-dependent regulatory
phenotype [13,14], or studying how these cells respond to cytokine
stimulation [15–17]. These studies have contributed significantly
to a better understanding of the mechanisms underlying Treg
mediated tolerance under physiological conditions. There are also
studies which have investigated Treg expression under diseased
conditions in mouse models for T1D [18,19]. Recent studies have
explored the expression signatures in peripheral blood mononu-
clear cells (PBMC) and in CD4
+ T cells of human T1D and T2D
subjects [20,21]. However, expression profiles in unfractionated
PBMC (or in the CD4
+ T cell subset) comprising a heterogeneous
cell population are difficult to correlate with expression changes
that should occur specifically in apoptosis-sensitive Tregs at the
onset of T1D.
In this study, we investigated the expression signature that
shapes the transcriptional program within functionally deficient
Tregs from recent-onset T1D. Expression profiles of unstimulated
Tregs from T1D subjects reveal a cellular response that could make
the cells sensitive to apoptosis, partially due to deprivation of
cytokines. This global picture of pathway-specific expression
signatures is a step further into dissecting Treg dysfunction in the
pathogenesis of T1D.
Results
Tregs from T1D subjects exhibit reduced suppressive
capacity and increased apoptosis
We first investigated a possible functional deficiency in Tregs
from T1D subjects, using a suppression assay. In a pilot
suppression assay, Tregs from healthy control subjects were co-
cultured with CD4
+CD25
2 effector T-cells (CD25
2 Teffs)a t
varying titrations of the Treg:CD25
2 Teff ratio (from 1:2 to 1:32)
and the suppressive capacity of Tregs was measured using the
formula described in the methods. Varying the CD25
2 Teff
numbers resulted in minor changes in suppression (Figure 1A).
Hence, we chose to carry out suppression assays at a 1:10 (Treg:
CD25
2 Teff) ratio for the rest of the study. Tregs from T1D subjects
(n=15) showed a significant reduction in suppressive capacity
compared to control subjects (n=17) (Mann-Whitney p,0.0007)
(Figure 1B). The raw CPM counts in single and co-culture were
comparable within the two phenotypic groups and the low
background counts confirmed that there was no media contam-
ination (Figure S1). We further checked if ongoing spontaneous
apoptosis could also be detected in Tregs from T1D subjects that
showed reduced function. We observed that Tregs from T1D
subjects had significantly elevated levels of apoptosis, compared to
control subjects (Mann-Whitney p,0.0001) (Figure 1C), but there
was no difference in apoptosis of CD25
2 Teffs across the two
phenotypes (Figure 1D). Also, while there was no difference in
apoptosis across Tregs and CD25
2 Teffs from the same control
subjects, Tregs displayed higher apoptosis levels compared to
CD25
2 Teffs cells from the same T1D subjects. A representative
flow cytometry plot for isolation of apoptotic cells is shown in
Figure S2.
These results strengthened the trends reported earlier by our
group in T1D subjects and at-risk non-diabetic individuals [10].
Furthermore, they suggest that in T1D subjects as well as in
normoglycemic at-risk subjects, Tregs undergo spontaneous apo-
ptosis in the periphery, which could result in a subsequent loss of
suppressive potential. Increased apoptosis and decreased suppres-
sion of Tregs observed in both recent-onset T1D subjects and in at-
risk individuals who have not yet been clinically diagnosed with
disease, indicates that these Treg defects are more a cause than an
effect of the disease.
Several reports have demonstrated that IL-2 is an important
signal for the development, function and homeostasis of natural
Tregs in-vivo [22–29]. Tang et al.[30] reported that in the NOD
mice (which spontaneously develops diabetes), disease progression
was associated with a loss of Treg: CD4
+Teff balance in the islets
with concomitant reduction of CD25 and BCL2 expression on
intra-islet Treg cells. Addition of IL-2 promoted Treg cell survival
and protected NOD mice from diabetes. Further, in the NOD
mouse, Yamanouchi et al. have shown that IL-2 gene variation
impairs Treg function and influences diabetes susceptibility. They
have also shown that the amount of IL-2 produced by autoreactive
CD8+ T cells in response to antigen seems to control the size of
the lymph node Treg pool [31]. Based on this collective evidence of
the role of IL-2 in Treg function, we hypothesized that reduced IL-
2 could be partially responsible for the increased apoptosis and
reduced function of Tregs from human T1D subjects. Further
evidence in support of this hypothesis is presented in the following
sections.
Increased apoptosis in Tregs from T1D subjects is
reproducible in healthy Tregs, under conditions of IL-2
deprivation
First, we tested if increased apoptosis could be reproducible in
healthy Tregs, under conditions of IL-2 and IL-4 deprivation. It
can be argued that it is more useful to establish the link between
cytokine deprivation and apoptosis directly in Tregs from T1D
subjects. However, functionally deficient Tregs from T1D subjects
are likely to undergo irreversible apoptosis/necrosis in response to
IL-2 deprivation, making this sort of analysis uninformative.
Apoptosis was measured in Tregs and in CD25
2 Teff cells from
control subjects, at 3 days and 5 days after IL-2, IL-4 and IL-2+IL-
4 withdrawal. Results show that there was increased apoptosis in
Tregs, but not in CD25
2 Teffs in response to IL-2 and IL-4
deprivation (Figure 2). Further, within Tregs, withdrawal of IL-2
leads to a strong apoptosis response, compared to withdrawal of
IL-4. Also, at 5 days of co-culture, the effect of IL-2-deprivation on
apoptosis was more pronounced. Remarkably, this pattern of
elevated apoptosis in healthy Tregs under conditions of IL-2
deprivation replicated that observed in Tregs from T1D subjects
when compared to control subjects.
Gene expression signatures in Tregs from T1D subjects
reveal modulation of several apoptosis genes, possibly
due to cytokine deprivation
We then proceeded to profile gene expression changes that
could discriminate functionally deficient and apoptosis-sensitive
Tregs from their healthy counterparts. Out of 16 T1D and 25
control subjects assayed for Treg apoptosis and suppression, 12
T1D and 15 control subjects yielded sufficient RNA for expression
profiling. Tregs were freshly isolated from PBMC and amplified
RNA was hybridized to the microarray as described in the
T-Cell Apoptosis in T1D
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tially regulated genes (|z-score|.20) across the two phenotypic
groups. Of these, 947 genes were upregulated in T1D subjects and
248 genes were downregulated in T1D subjects, compared to
control subjects. Tregs used in this expression study were not
subjected to any stimulation, as these cells are known to be
susceptible to activation-induced cell death, whereby any resulting
differences in apoptosis-related gene expression could be nullified
[32,33]. Hence the relatively modest magnitude of expression
changes (62.5-fold or less) was expected in this dataset. It is now
known that for minimal changes in gene expression, instead of a
gene-by-gene approach [34], detecting predefined co-regulated
gene sets for association with disease phenotypes has more power
of discovering biological themes within functionally related sets of
genes. We used EASE, a pathway enrichment tool, to find the
biological pathways perturbed in each phenotype [35]. Within
EASE, three functional categorization systems, viz. Organismal
role, GO Molecular function and Interpro were probed individ-
ually for pathway terms associated with each of the two
phenotypes. To rank pathway terms by over-representation, we
used the significance cutoffs on the EASE score (see the methods
section for details on the EASE score). The 5 most significantly
enriched pathway terms and associated EASE scores under each
of the three categorization systems are shown in Table 1. For the
gene list downregulated in T1D subjects, there was a near-
significant enrichment (EASE score,0.06) of terms related to cell
migration/motility, cytokine binding, MHC class II receptor activity,
chemokine receptor activity, chemokine receptor & MHC Class II, alpha
chain.
Next, we extracted the identities and annotations of the genes
that featured in the enrichment results, as well as other
differentially expressed genes that are members of these functional
clusters. These differentially regulated genes are shown in Figure 3,
along-with their functional grouping and associated fold changes.
Our primary observation was that several apoptosis-related genes
were differentially regulated in Tregs from T1D subjects, compared
to control subjects (all significant at |z-score|.20). BCL2, an anti-
apoptotic gene which represses the caspase cascade and is known
to make CD4
+ T cells sensitive to apoptosis under conditions of
serum starvation [36], was downregulated in T1D subjects.
Cytochrome c (CYCS), whose release from the mitochondria is
normally blocked by BCL2, as well as FAS and BCL10- two major
caspase activators, were also upregulated in Tregs from T1D
subjects. Further, genes related to stress response and known to be
Figure 1. In T1D subjects, Tregs isolated from CD4
+ T cells have
reduced function and increased apoptosis. Standard in vitro
suppression assay included 25,000 responder CD4
+CD25
2 T cells that
were set up as single culture as well as with CD4
+CD25
high T cells in co-
culture, both with added 25,000 of irradiated PBMCs (as antigen-
presenting cells) which were stimulated with aCD3-coated beads (1 mg/
ml) for 5 days. Ratio of responder and CD4
+CD25
high T cells was varied.
Suppressors were seeded with APC in separate wells to measure their
own proliferation in respond to the same stimulation. Bars are
mean6SEM of three independent observations. (B) Suppression
potential of isolated CD4
+CD25
high T-cells measured by an in vitro
proliferation assay in T1D (n=17) and control (n=15) subjects. A
standardized suppression assay was performed with 2.5610
4
CD4
+CD25
2 effector T-cells (with 2.5610
4 irradiated PBMC -5000rad)
in co-culture with CD4
+CD25
high T-cells at a 1:10 ratio (CD4
+CD25
high:
CD4
+CD25
2), stimulated with aCD3 coated beads (1 ug/ml, 3 beads/per
cell). Apoptosis results following YOPRO-1/7AAD staining for (C)
CD4
+CD25
high (T1D: n=16, controls: n=25) and (D) CD4
+CD25
2 T-cells
(T1D: n=15, controls: n=17) are both presented as % apoptotic
(YOPRO1+ve) amongst live cells (7AAD–ve).
doi:10.1371/journal.pone.0006527.g001
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from T1D subjects. The transcription factor FOXO3A as well as
some its key pro-apoptotic transcriptional targets (GADD45A,
GADD45B, SESN1, CDKN1B, CITED2 and TNFRSF10B) were
upregulated in Tregs from T1D subjects. Pro-apoptotic genes in the
p53 signaling pathway (STK17A, STK17B, GADD45A, GADD45B,
Figure 2. Under conditions of IL-2 and IL-4 withdrawal, apoptosis in healthy Tregs mimics the increased apoptosis in Tregs from T1D
subjects. Apoptosis was measured in (A) healthy Tregs and (B) CD4
+CD25
2 effector T-cells at 3 days and 5 days, in response to IL-2 and IL-4
deprivation as described in the methods. Overall, in response to IL-2- and IL-4- deprivation, Tregs show more apoptosis compared to effector T-cells.
Further, within Tregs, withdrawal of IL-2 leads to a strong apoptosis response, compared to withdrawal of IL-4. Also, this difference in apoptosis was
more prominent after 5 days of IL-2 withdrawal. The bars depict the mean6SEM of six independent observations.
doi:10.1371/journal.pone.0006527.g002
Table 1. Pathway enrichment analysis using EASE.
EASE score Gene Category EASE score
Organismal role Organismal role
General cellular role 3.73E-05 * Anti-pathogen response 2.92E-02
Angiogenesis 8.77E-02 Cell migration/motility 5.83E-02
Cell death/Apoptosis 1.18E-01 Pathogenic Invasion 6.68E-02
Anti-pathogen response 1.40E-01 Neuronal development 3.01E-01
Control of Cell Proliferation 5.47E-01 Other development 6.35E-01
GO Molecular Function GO Molecular Function
Nucleic acid binding 9.92E-08 * Cytokine binding 9.00E-05
Hydrogen ion transporter activity 1.16E-07 * MHC class II receptor activity 1.28E-04
Monovalent inorganic cation transporter activity 3.70E-07 * Transmembrane receptor activity 1.34E-04
RNA binding 2.13E-06 * C-C chemokine binding 2.46E-04
Cation transporter activity 3.02E-05 * C-C chemokine receptor activity 2.46E-04
Interpro Interpro
Helicase C-terminal domain 1.08E-02 * Chemokine receptor 5.93E-03
DEAD/DEAH box helicase 1.08E-02 * Immunoglobulin C-type 2.94E-02
ATP-dependent helicase, DEAD-box 1.80E-02 * MHC Class II, alpha chain 3.21E-02
Proline rich extensin 3.52E-02 * Ras GTPase-activating proteins 7.33E-02
Spectrin repeat 6.44E-02 Immunoglobulin and MHC domain 1.12E-01
Left panel): Top 5 terms amongst the 948 genes upregulated in T1D (FDR,5%), in each of the three functional classification systems. (Right panel): Top 5 terms amongst
the 257 genes downregulated in T1D (FDR,5%), in each of the different functional classification systems. Terms marked with an asterisk (*) are statistically significant at
EASE score ,0.05
doi:10.1371/journal.pone.0006527.t001
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subjects. Finally, several members of the GIMAP gene family
(implicated with T1D in the rat [38–40]), HLA genes as well as
cytokine/chemokine receptors were downregulated in Tregs from
T1D subjects. In summary, the downregulation of AKT1 and the
concomitant upregulation of FOXO3A/p53 targets in Tregs from
T1D subjects mirrored a cytokine deprivation mediated stress
response that could lead to AKT pathway mediated cell cycle
arrest.
For confirmation of array results by quantitative RT-PCR, we
restricted the selection of apoptosis-related and HLA Class I/Class
II genes to only those that were reported as differentially expressed
using both SAM (FDR,10%) and BGX (|z-score|.20) analyses.
RT-PCR results (Figure 4) confirm the upregulation of PTEN,
FAS, as well as several pro-apoptotic transcriptional targets of
FOXO3A in Tregs from T1D subjects (GADD45A, GADD45B,
SESN1, PUMA and TNFRSF10B). Downregulation of CCND2,a
negative target of FOXO3A, was also confirmed. Trends in the
expression of HLA Class I (HLA-A, HLA-C, HLA-E) and HLA
Class II genes (HLA-DQA1, HLA-DQB1, HLA-DRB1, HLA-DRA1)
were similar to those observed on the array. In agreement with the
array results, GIMAP5 was also found to be downregulated by RT-
PCR. Thus, RT-PCR results confirm several array results, and
establish the expression changes in the AKT pathway that make
Tregs from T1D subjects sensitive to apoptosis.
For reproducing expression signatures seen in Tregs from T1D
subjects, we selected 32 key genes from the various functional
clusters discussed so far (15 apoptosis-related genes, 11 cytokine &
chemokine receptors and 6 GIMAP genes), and checked their
expression trends in healthy Tregs, under conditions of IL-2
deprivation. As array results suggested early gene expression
changes leading to apoptosis, we checked RNA expression at 12
hours, 24 hours and 3 days after IL-2 withdrawal. Results show
that expression trends in TCR-Co (aCD3+aCD28) stimulated
healthy Tregs under IL-2 withdrawal were in agreement with
expression trends in Tregs from T1D subjects, for 19 of the 32
assayed genes (Figure 5). Expression trends in key apoptosis genes
along the AKT/p53 signaling axis (upregulation of transcriptional
targets of FOXO3A: TNFRSF10B, GADD45A, GADD45B and FAS)
and cytokine/chemokine receptors (downregulation of IL1R1,
CCR2, CCR6, CD58 and CXCR3) mimic those observed in Tregs
from T1D subjects, at one or more time-points. Further, in the
gene-expression results, important cytokine-responsive lymphocyte
activation markers: interleukin-2 receptor alpha (IL2RA), chemo-
kine (C-C motif) receptor 5 (CCR5) and human leukocyte antigen,
class II, DR alpha 1 (HLA-DRA1) were downregulated in Tregs
Figure 3. Expression trends of differentially regulated apoptosis genes on the array. This panel of genes shows the identity, functional
grouping and the fold change of genes differentially regulated across T1D and control subjects (|z-score|.20). The red bars represent genes that are
upregulated in T1D subjects compared to controls and the green bars represent genes that are downregulated in T1D subjects compared to controls.
The fold changes are as reported by BGX analysis. The gene symbols with an asterisk (*) represent genes whose expression was confirmed on the
microarray as well as by RT-PCR.
doi:10.1371/journal.pone.0006527.g003
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activation-linked genes are positively regulated by IL-2 in various
T-cell subsets [41,42]. In line with our hypothesis, withdrawal of
IL-2 resulted in reduced expression of these cytokine-responsive
genes.
In summary, expression trends in healthy Tregs under cytokine
deprivation were identical to those observed in Tregs from T1D
subjects. These lines of evidence support the hypothesis that the
expression signature in Tregs from T1D subjects may be partially
induced by a cytokine deficient milieu. A pathway diagram in
Figure 6 captures the multiple signaling events that could trigger
apoptosis in Tregs from T1D subjects, under conditions of cytokine
deprivation.
Discussion
IL-2, a T-cell growth factor, plays an important role in multiple
aspects of T-cell biology. Apart from the effect of IL-2 on Treg
activation, there is strong evidence supporting a role for IL-2 in the
development and/or function of Tregs [25,26,43]. In close
proximity to Tregs in vivo, are effector T-cells which control Treg
development and function by secreting several cytokines, including
IL-2. There is evidence for an imbalance in cytokine secretion
from effector cells in T1D [44]. In the murine TS1ab cell line,
following IL-2-deprivation, there was decreased proliferation and
increased apoptosis over time [45]. Some studies have reported
decreased IL-2 production in recent-onset T1D patients and low
IL-2 production persisting for years after the onset of disease
[46,47]. Treg stimulation occurs in vivo by cytokines secreted from
various effector cell types, but the CD4+ effector T cells which are
the major producers of IL-2, play a primary role in shaping the
Treg maturation and response. We also compared the production
of cytokines in both the CD4
+CD25
2 and the CD4
+CD25
low
effector T-cell subsets from T1D and control subjects. As shown in
Figure S3, for both these effector T-cell subsets, after 12 hours of
aCD3 and aCD28 stimulation, production of some important
cytokines (IL-2, IL-4, IL-5, IL-10, IFNc and TNFa) was reduced
in T1D subjects compared to control subjects, with the maximum
difference in levels of IL-2 secretion (p,0.05 for IL-2,
CD4
+CD25
2). Further, although differences in the production
of other cytokines across the two groups were not statistically
significant, the trends were similar for each of the measured
cytokines. These results collectively suggest that increased
apoptosis, decreased Treg function and concomitant gene expres-
sion changes could be linked to deficient IL-2 secretion from
effector T-cells.
In line with this hypothesis, we observed elevated Treg apoptosis
and reduced Treg suppressive function at the onset of disease.
Considering that Tregs are selective targets for destruction,
expression profiling within Tregs provided us with a model for
understanding the cause (Treg environment) by studying the effect
(Treg expression changes). Our data supports the notion that in
patients with T1D, the lack of suppression of autoreactive T-cells
in the periphery is a result of increased apoptosis in Tregs, possibly
precipitated by deprivation of growth signals such as IL-2.
Increased expression of various apoptosis genes, and the
downregulation of pro-survival GIMAP genes indicate a complex
interplay amongst these pathways leading to apoptosis. Further,
co-ordinate repression of cytokine receptors and HLA genes points
to a possible proliferation defect in Tregs from T1D subjects.
The FOXO subfamily of forkhead transcription factors plays an
evolutionarily conserved role in cellular adaptation to stress stimuli
and also regulates survival in response to cytokine deprivation,
DNA damage and oxidative stress. Amongst several reports
documenting apoptosis of lymphoid cells under conditions of
cytokine deprivation [48,49], there is increasing evidence for the
involvement of the PI3K/AKT and the closely intertwined p53
signaling pathways [50–53]. Further reports have shown that
under conditions of cytokine deprivation mediated cellular stress,
AKT-mediated activation of FOXO3A and subsequent transcrip-
tional regulation by FOXO3A leads to cell cycle arrest and
apoptosis [54,55]. In Tregs from T1D subjects, we observe AKT to
be downregulated, while PTEN and FOXO3A are upregulated,
suggesting that in the absence of activated AKT, FOXO3A
phosphorylation may be inhibited, which could lead to its
activation and translocation to the nucleus. Transcriptionally
active FOXO3A induces several pro-apoptotic genes such as
PUMA, BIM, GADD45A, GADD45B, SESN1, TNFRSF10B, CIT-
ED2 and CDKN1B, all of which were upregulated in Tregs from
T1D subjects (significant either on the array at |z-score|.20 or
on RT-PCR at p,0.05) as well as show similar trends in healthy
Tregs under conditions of IL-2 withdrawal. Our data suggests that
in Tregs from T1D subjects, both the AKT and p53 pathways exert
pro-apoptotic function through transcriptional regulation of
multiple downstream targets that render the cells sensitive to
apoptosis.
Few studies have reported on the expression of HLA molecules
in T-cells of patients with T1D. HLA class I expression has been
Figure 4. Confirmation of array results by RT-PCR. Expression
results for several genes in the AKT pathway and HLA genes were
confirmed by RT-PCR. For genes in the AKT pathway, the expression
value is a ratio of the average expression across T1D subjects (n=5) to
the average expression across control subjects (n=5). For HLA Class II
genes, the expression value is a ratio of the average expression across
T1D subjects (n=6) to the average across controls subjects (n=8). For
HLA Class I genes, the expression value is a ratio of the average across
T1D subjects (n=10) to the average across control subjects (n=10).
Genes for which the expression ratios were statistically significant
(Mann-Whitney p#0.05) are marked with an asterisk (*). Subjects are
not the same as those used for expression profiling.
doi:10.1371/journal.pone.0006527.g004
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class II expression on the surface of PBMC of T1D patients has
been reported to be normal [56]. Reduced expression of HLA
Class I as well as Class II molecules in freshly isolated Tregs from
T1D subjects could lead to defects in HLA-TCR interactions
between Tregs and various other T-cell subsets in the periphery.
Recently, it has been demonstrated that the direct ex vivo
expression of HLA-DR in the context of CD4
+CD25
high T cells
identifies a mature, functionally distinct regulatory T cell
population involved in contact-dependent in vitro suppression[59].
Our observation of reduced HLA Class II in Tregs from T1D
subjects and the associated loss of suppressive capacity is in line
with this report. We are currently following up this relationship
across HLA expression, Treg function and genotype as a separate
study.
Several genes in the GIMAP family of novel GTPases (GIMAP4,
GIMAP5, GIMAP1, GIMAP7 and GIMAP8) are also downregulated
in Tregs from T1D subjects. Recent reports suggest crucial roles of
GIMAP family proteins in regulating T-cell development, selection
and homeostasis [60,61], and GIMAP4/5 have been shown to
interact with BCL2 family members, thereby regulating T-cell
survival [39]. GIMAP5 gene mutations have been shown to
contribute to T1D in the rat model for diabetes [62,63]. As the
downregulation of GIMAP genes in Tregs from T1D subjects could
not be reproduced in healthy Tregs under IL-2 withdrawal, the IL-
2 pathway does not seem to control expression of GIMAP genes.
It is interesting to observe that some of the differentially
expressed genes in this study have been discussed in other Treg
gene expression studies, in both the physiological and disease
contexts. Amongst a subset of direct FOXP3 targets that exhibited
consistent transcriptional behavior in hybridomas and in ex vivo T-
cells [64], we found several negative targets of FOXP3 (EVI2B,
GADD45B, PTPN22, TGIF, MYC, PHF6, POU2AF1 and GPR171)
to be upregulated in Tregs from T1D subjects while positive
FOXP3 targets (IL2RA, CD2 and CPEB2) were downregulated in
Tregs from T1D subjects. In summary, our results provide evidence
that dysregulation in Treg specific as well as FOXP3 associated
genes could lead to functionally compromised Tregs in T1D
subjects.
Our study design has some limitations. First, Our Treg isolation
strategy may not be the most optimal way to isolate pure Tregs.
However, isolation of bonafide regulatory T-cells remains difficult
because the availability of specific marker molecules is still limited.
Apart from CD25, additional surface molecules have been
proposed as useful markers to distinguish regulatory from effector
T-cells, such as CTLA4, TNFRSF18 (GITR), CD62L and NRP1.
However, many of these molecules are also expressed by naı ¨ve
CD4
+CD25
2 T-cells upon activation, thereby hampering dis-
crimination between regulatory and conventionally activated
CD4
+ T-cells. Here we adopted a very conservative Treg isolation
strategy, selecting only the top 1% CD25 expressing cells as Tregs.
The additional confirmation that most of these cells were CD127-
Figure 5. Under condition of IL-2 withdrawal, expression changes of key apoptosis and cytokine/chemokine genes in healthy Tregs
are similar to those observed in Tregs from T1D subjects. Expression changes in 32 selected genes were captured in healthy Tregs treated with
aCD3+aCD28 with or without anti-IL-2, for indicated time points. The figure shows a subset of apoptosis and cytokine/chemokine receptor genes,
whose expression trends in IL-2-deprived healthy Tregs were similar to those in Tregs from T1D subjects. Red bars indicate genes upregulated on IL-2
deprivation and green bars indicate genes downregulated on IL-2 deprivation in healthy Tregs. The bars depict the mean6SEM of three independent
observations.
doi:10.1371/journal.pone.0006527.g005
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(Figure S4-A). Second, subjects in both groups belonged to
different age groups. However, we have earlier shown that the
apoptosis of Tregs is not related to age effects [65]. Third, although
it would be more useful to confirm the results on apoptosis and
cytokine receptor genes directly on Tregs from T1D subjects, we
had to use healthy Treg blood-donor subjects for lack of adequate
numbers of fresh Tregs from children with T1D. Further,
subjecting Tregs from T1D subjects to IL-2 deprivation would
have not have much use, as they are already in an environment of
cytokine deprivation. Nevertheless, the expression of pro-apoptotic
genes in Tregs from healthy subjects under conditions of IL-2
deprivation mimicked the behavior of the same genes in Tregs from
T1D subjects, which gives indirect yet convincing evidence in
support of our hypothesis. Lastly, with this study design, it is not
possible to determine precisely the extent to which the expression
profile associated with the T1D phenotype could be mediated by
possible secondary effects of insulin or hyperglycemia. However,
we have previously shown that long-standing T1D subjects as well
as longstanding T2D subjects who are also on insulin do not show
the same Treg defects as in the at-risk or recent-onset T1D subjects
[10]. Hence, it is unlikely that there is any significant effect of
exogenous insulin or hyperglycemia on Treg apoptosis.
To conclude, this report establishes the expression signature
within Tregs in the periphery, during the period right after the
clinical onset of T1D. Tregs in T1D subjects express several pro-
apoptotic genes, specifically along the AKT- and p53- signaling
axis, which may be partially a result of cytokine deprivation. This
identification of a molecular signature of Tregs during the recent-
onset T1D period is an important step in understanding Treg
action and could serve as an important diagnostic for Tregs that
have lost the potential to suppress autoreactive effector cells.
Figure 6. Putative cytokine deprivation mediated apoptosis signaling pathways in Tregs from T1D subjects. In the absence of cytokines
or growth factors, the stress-induced PI3K-AKT pathway and the p53 pathway are activated. Downregulation of PI3K and AKT through inhibition by
PTEN leads to translocation of dephosphorylated FOXO3A into the nucleus. Nuclear FOXO3A activates several pro-apoptotic genes (PUMA, BIM,
SESN1, TNFRSF10B, CDKN1B, CITED2) and represses CCND2 (a cell cycle gene) by direct transcriptional control. Modulation of these FOXO3A targets
then leads to cell cycle arrest and apoptosis. On the other hand, activation of p53 further represses AKT via induction of PTEN, and also leads to a
cascade of expression changes in several apoptosis genes. Activation of p21 and the two GADD45 genes leads to cell cycle arrest at the G1 and G2
phases respectively. Ligation of TRAIL with TNFRSF10B (TRAILR) and activation of FAS on the surface of Tregs triggers the extrinsic apoptosis pathway,
leading to the release of cytochrome c from the mitochondria and activation of the caspase cascade. This complex signaling involving cytokine-
deprivation mediated activation of both the intrinsic pathway as well as the extrinsic pathway leads to increased Treg apoptosis in T1D subjects.
Genes with red triangles were upregulated, while genes with green triangles were downregulated in Tregs from T1D subjects (|z-score|.20 on the
array). This pathway diagram is constructed using known gene-gene interactions from the literature, for those genes that were discussed in this study
either on the array, RT-PCR or under conditions of IL-2-deprivation.
doi:10.1371/journal.pone.0006527.g006
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T1D induces expression of apoptotic genes will reveal novel points
along the death-promoting cascade, which can be targeted for
therapeutic interventions.
Materials and Methods
Ethics Statement
The research protocol was approved by the Institutional Review
Board (IRB) of the Children’s Hospital of Wisconsin IRB no. 01–
15 and participants and/or their parents (guardians) provided
written informed consent.
Human subjects and clinical measurements
Recent-onset T1D subjects (after stabilization on exogenous
insulin but within 12 months of diagnosis; n=15) were recruited
through the diabetes program at Children’s Hospital of Wisconsin.
Diabetes was defined according to World Health Organization
criteria and included blood glucose levels of .200 mg/dl with
symptoms confirmed by a physician [66]. Healthy control (n=17)
subjects were recruited by posting flyers in Children’s Hospital of
Wisconsin and the Medical College of Wisconsin. The control
criteria comprised fasting blood glucose of ,100 mg/dl, no
familial history of any autoimmune disorder, and negativity for
islet autoantibodies at the 99th percentile. All study subjects were
free of known infection at the time of sample collection. At the
time of each visit, the following clinical measurements were taken:
HbA1c, glucose level, height, weight and BMI (subject character-
istics are shown in Table 2). The presence of autoantibodies was
measured from peripheral blood.
CD4
+CD25
high T-cell isolation
As this study assessed whether alterations in the function of
regulatory T-cells could be involved in the pathogenesis of T1D, it
was crucial to identify highly pure and homogeneous regulatory T-
cells. It is now known that while the entire population of
CD4
+CD25
+ T-cells, expressing both low and high CD25 exhibits
regulatory function in the mouse, only the CD4
+CD25
high
population exhibits a similarly strong regulatory function in
humans [67–69]. Using the same FACS isolation protocol
described earlier [10], we collected the top 1% of CD4
+CD25
high
T-cells as Tregs for this study. CD4
+CD25
low and CD4
+CD25
2
effector T cells were also isolated using the same protocol. This
additional stringency of collecting just the top 1% of
CD4
+CD25
high cells as Tregs ensured removal of most of the
activated CD25
low T-cells. We found that most of the Tregs we
isolate are CD127-ve [70,71], while most of the CD4
+CD25
2 cells
are CD127
+, as an added confirmation of the purity of the isolated
Tregs. See Supporting Fig. S5-A for a representative plot of this
standardized sorting procedure. Further, as shown in Figure S4-B,
intracellular staining for FOXP3 positivity also showed that Tregs
isolated using this protocol had a significantly higher percentage of
FOXP3
+ cells (61.8862.68) compared to CD4+CD25 ¯ cells
(4.3260.80) (Mann-Whitney p,0.0001). Isolated Treg cells were
anergic and showed good suppressive capacity in vitro (data not
shown). Thus, our isolation protocol generated Tregs that
maintained high level of sustained FOXP3 expression associated
with phenotypic and functional stability.
RNA extraction and hybridization
Total RNA was extracted from CD4
+CD25
high T-cells using
TRIzol Reagent (Invitrogen Life Technologies) according to the
manufacturer’s protocol. The GeneChip human genome U133
plus 2.0 array (Affymetrix) was selected for this study which
interrogates .47,000 probe sets, representing roughly 39,000
unique genes. Purified total RNA (,50 ng) was amplified using an
Affymetrix two-cycle cDNA synthesis kit (catalog no. 900432) and
cRNA was synthesized, labeled, fragmented and hybridized to the
arrays in accordance to standard Affymetrix protocols. After
hybridization arrays were washed, stained with PE-conjugated
streptavidin (Molecular Probes) and scanned on a GeneChip
Scanner 3000 (Affymetrix). Image data were analyzed with
Affymetrix GeneChip operating software (GCOS).
Microarray quality control
Each microarray scan was visually inspected for irregularities,
and the quality of the entire microarray set was assessed using the
affyQCreport package from the Bioconductor project [72]. Infor-
mation from the various QC plots (Figure S5) confirmed good data
quality across arrays.
Bayesian hierarchical analysis
Most existing methods for studying differential expression adopt
a stepwise procedure for obtaining a point estimate of expression
for each gene on each array. Having obtained point estimates for
all the genes, studies of differential expression between pairs of
Table 2. Subject demographics and clinical measurements.
Recent-onset T1D Healthy Controls
Number of subjects 12 15
Gender 4M/8F 5M/7F
Age at visit (years) 13653 5 614
Height (cm) 153619 16969
Weight (kg) 47618 67614
BMI 19632 3 63
Glucose (mg/dl) 203679 87612
Duration of T1D (months) (range: 0.48–10.56) 4.463.3 NA
HbA1c (%) 760.8 NA
Insulin dose (ave.units/kg/day) (range: 0.05–0.75) 0.4660.27 NA
NA=Not Applicable
doi:10.1371/journal.pone.0006527.t002
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estimates under the phenotypes, using a t-type statistic such as in
SAM [73], Cyber-T [74] or Limma [75], all of which rely on the
availability of replicate subjects in each phenotypic condition, for
estimation of variances. These approaches are not feasible when
the number of subjects is low. As limitations on the amount of
available RNA restricted our analysis study to a limited number of
subjects in each phenotype, we used Bayesian Gene eXpression,
BGX [76-78], which implements a statistical procedure that works
with minimal or no replicates in each phenotypic group. The BGX
method differs from these stepwise point estimate approaches in
that (1) uncertainties associated with each of the steps are taken
into account at all levels of analysis, (2) gene- and phenotype-
specific expression levels are estimated from a joint consideration
of the available probe set intensities and (3) the outcomes are
posterior distributions of expression rather than point estimates. A
flowchart for all steps of this analysis is shown in Figure S6. The
program was executed with the following parameter values:
number of probes: 604258; number of genes: 54675; number of
categories: 1, number of probes with no sequence information: 0;
number of genes to monitor fully: 0; sub-sampling interval: 16;
number of burn-in sweeps: 8192; number of sampling sweeps:
16384; spread of jumps in S: 30; spread of jumps in H: 350; spread
of jumps in mu: 1.1; spread of jumps in sigma: 1.5; spread of jumps
in lambda: 0.04; spread of jumps in eta: 0.1; batch size: 50 and
optimal acceptance ratio: 0.44. Briefly, in the first step, a Bayesian
hierarchical model is formulated for estimating expression levels
from probe level expression data from all the arrays. For each gene
in each phenotype (phenotype 1: T1D and phenotype 2: Control),
the gene expression index mg1 (level of expression of gene g in T1D)
and mg2 (level of expression of gene g in Controls) is calculated.
Within this framework, the samples from the posterior distribu-
tions of the differences (dg=mg,1 2 mg,2, g=1,…54675) represent a
natural base for inference on differential expression. For each
gene, a kernel density plot for the expression index mgp and the
difference dg was constructed. From the cumulative information of
expression differences (dg, g=1 to 54675), a histogram of the
posterior probabilities of expression differences being less than
zero [P(dg,0),g=1, …54675] is determined (Figure S7). The null
distribution is estimated by spline fitting [79] on the histogram,
and the difference between the histogram fit (grey curve) and the
null distribution (black curve) is used to give an estimate of the
number of differentially expressed genes. An excess of P(dg,0)
values in the left as well as right tails indicates the presence of both
over- and under-expressed genes respectively. In the final step,
genes are ranked using the standardized BGX difference (z-score)
between the two conditions, which takes into account the
estimated difference in expression level as well as the associated
uncertainty. The z-score also takes into account the autocorrela-
tion structure of the sequence of values generated by the
algorithm, whereby genes with highly autocorrelated values (high
variability) are automatically given lower ranks, thereby increasing
the power to detect differential expression. The identities of the
differentially expressed genes are found by selecting from each end
of the ranked list, the number of differentially expressed genes
predicted to be in the tails of the histogram of posterior
probabilities. The analysis predicted a total of 1205 differentially
expressed genes, of which 948 genes were upregulated in T1D (left
tail of the histogram) and 257 genes were downregulated in T1D
(right tail of the histogram). Although rank thresholds from the
histogram were used instead of an arbitrary z-score threshold for
picking differentially expressed genes, all genes within the list of
1205 differentially satisfied the |z-score|.20 threshold, which has
been shown to yield a low ,5% FDR on the Golden spike control
dataset [76]. There was a 78% overlap among differentially
expressed genes predicted through BGX (FDR,5%) and SAM (t-
test, FDR,9.5%), which verifies the predictive accuracy of this
new Bayesian technique, when compared to a frequentist
approach. These data have been deposited in NCBI’s Gene
Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/)
and are accessible through GEO Series accession number
GSE10586.
Gene annotation and pathway enrichment analysis
Gene annotation was carried out using controlled vocabularies
from the Gene Ontology database [80]. Information from gene-
gene interactions on multiple KEGG pathways (http://www.
genome.jp/kegg) was assimilated for constructing the putative
signaling diagram shown in Fig. 6. Pathway enrichment analysis
was carried out using EASE [35]. Briefly, in EASE, the following
terminology is used for pathway enrichment analysis: List
Hits=number of genes in the gene list that belong to the Gene
Category; List Total=number of genes in the gene list; Population
Hits=number of genes in the total group of genes assayed that
belong to the specific Gene Category; Population Total=number
of genes in the total group of genes assayed that belong to any
Gene Category within the System. The first step is the mapping of
primary gene identifiers to gene categories within various
categorical systems. Then, the ‘‘Population Total’’ is determined
for each system of gene categorization, and the ‘‘Population Hits’’
is determined for every category within those systems. Now given a
gene list that represents some sub-set of the population genes, the
‘‘List total’’ and ‘‘List Hits’’ counts can be determined. The
probability of seeing the number of ‘‘List Hits’’ in the ‘‘List Total’’
given the frequency of ‘‘Population Hits’’ in the ‘‘Population
Total’’ is calculated as the EASE score. The EASE score is
essentially a sliding-scale, conservative adjustment of the Jackknife
Fisher exact probabilities that strongly penalizes the significance of
categories supported by few genes and negligibly penalizes
categories supported by many genes, therefore yielding more
robust results.
Real-Time PCR analysis
Total RNA (25 to 50 ng) was converted to cDNA using the
QuantiTectH reverse transcription kit (Qiagen). Real-time PCR
was then performed using the QuantiTectH SYBR Green PCR
Kit (Qiagen) on an ABI Prism 7900HT sequence detection system
machine with SDS software (Applied Biosystems). Manufacturer
protocols were followed for all procedures. mRNA gene-
expression was quantified relative to either GAPDH or 18 s
rRNA housekeeping genes. Using the Oligo 6 software (Molecular
Biology Insights), primer sets for each gene were designed towards
the same region of cDNA that was represented by the probe sets
on the Affymetrix GeneChip arrays.
Apoptosis assay
Apoptosis was measured using a dual-staining method that our
group has reported to be very sensitive for apoptosis detection
[81]. Briefly, 15,000–25,000 CD4
+CD25
high T-cells were stained
with YOPRO1 (250 nM) for 20 minutes in the dark and 7AAD
(250 ng) was added 10 minutes before acquiring events on a FACS
LSRII (BD Biosciences). The data was then analyzed using the
FACSDiva Software (BD Biosciences). Apoptosis was measured as
the percentage of apoptotic cells YOPRO1+ve/7AAD-ve amongst
live cells (total 7AAD-ve cells comprising both YOPRO1+ve and
YOPRO1-ve cells).
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CD4
+CD25
2 T-cells (2.5610
4 cells/well) were cultured in
RPMI 1640 media supplemented with 2 mM L-glutamine,
5 mM HEPES, 100 U/mg/ml penicillin/streptomycin, 0.5 mM
sodium pyruvate and 10% human AB serum. Cells were
stimulated with aCD3 coated beads (1 mg/ml, 3 beads/cell) in
U-bottom 96 well plates (Costar) in the presence of the same
number of irradiated autologous PBMC for 5 days. For the
suppression assays CD4
+CD25
high T-cells were co-cultured with
CD4
+CD25
2 at a 1:10 ratio (Treg:CD25
2 Teff) using the same
stimuli. Cells were pulsed with 1 mCi of [
3H] thymidine
(Amersham Pharmacia Biotech) and harvested after 16 hours.
The cpm per well was determined with a scintillation counter (Top
Count NXT, Packard). The percentage of suppression was
calculated as {(s2c)/s}6100%, where s=cpm in single culture
and c=cpm in co-culture.
Intracellular Staining for FOXP3
Intracellular staining for FOXP3 was carried out in 15,000–
25,000 CD4
+CD25
high T-cells using the PE Anti-Human FOXP3
Staining Set (eBioscience) following the recommended protocol.
Cells were first fixed, washed and permeablized, then stained with
either FOXP3-PE (clone PCH101) or the isotype control rat
IgG2a-PE. Intracellularly stained cells were then analyzed on a
FACS LSRII using FACSDiva Software (BD Biosciences).
Cytokine measurement from CD4
+CD25
low cells
CD4
+CD25
low cells were plated at 50,000 cells per well and
stimulated with platebound aCD3 (5 mg/ml) and soluble aCD28
(2.5 mg/ml) (BD Biosciences) at 37uC/5%CO2. After 55 hours,
100 ul of supernatant was removed from each well and stored at
280uC until the cytokines were measured. The supernatants were
thawed and 50 ml was used in the Cytometric Bead Array (CBA)
Human Th1/Th2 Cytokine Kit (BD Biosciences). The assay was
performed according to the manufacturer’s recommended proto-
col. The samples were acquired on a FACSCalibur (BD
Biosciences) following the cytometer setup protocol. The FACS
data was analyzed using the CBA 6 bead analysis software (BD
Biosciences).
Apoptosis assay during cytokine deprivation
CD4
+CD25
high and CD4
+CD25
2 T-cells were isolated from 6
buffy coats by FACS sorting as previously described in the cell
isolation procedure above. Cells were plated at 75,000 cells per
well under the following 6 conditions: TCR-Co (1 mg/ml plate-
bound aCD3, clone UCHT1, Ancell and 0.5 mg/ml soluble
aCD28, clone CD28.2, BD Biosciences); TCR-Co+IL-2 (200 U/
ml, human-recombinant, BD Biosciences); TCR-Co+anti-IL-2
(2 mg/ml, clone MQ1-17H12, BD Biosciences); TCR-Co+IL-4
(200 U/ml, recombinant, BD Biosciences); TCR-Co+anti-IL-4
(1 mg/ml, clone MP4-25D2, BD Biosciences); and TCR-Co+anti-
IL-2 (2 mg/ml)+anti-IL-4 (1 mg/ml). The cells were incubated at
37uC/5% CO2 and at the indicated time points (12, 24, 72 and
120 hours), the cells were removed from the wells and 25,000 cells
were used to measure apoptosis as previously described in methods
above. The remaining 50,000 cells were resuspended in TRIzol
Reagent (Invitrogen) and stored at 280uC until RNA could be
isolated.
Supporting Information
Figure S1 Raw proliferation counts (cpm) for suppression assay.
T-cell proliferation (cpm) in media only (background), single
culture (only CD25- Teffs) and in co-culture (Tregs and CD25-
Teffs) for both the phenotypic groups is shown for the suppression
results shown in Figure 1 in the manuscript. Values shown are
mean6SE across the number of samples indicated for Figure 1.
Found at: doi:10.1371/journal.pone.0006527.s001 (0.03 MB TIF)
Figure S2 Representative flow cytometry plot for measurement
of Treg Apoptosis. Figure shows one representative FACS plot for
measurement of Treg apoptosis, as described in the methods
section. Apoptosis was measured as the percentage of apoptotic
cells YOPRO1+ve/7AAD-ve (green) amongst live cells (total
7AAD-ve cells comprising both YOPRO1+ve and YOPRO1-ve
cells, blue+green).
Found at: doi:10.1371/journal.pone.0006527.s002 (0.09 MB TIF)
Figure S3 Cytokine production from CD4+CD25- and
CD4+CD25low effector T cell subsets. Production of some
important cytokines was measured by a CBA assay, as described
in the methods. Results are average values across indicated
number of subjects, for (A) CD4+CD25- and (B) CD4+CD25low
effector T-cell subsets.
Found at: doi:10.1371/journal.pone.0006527.s003 (0.03 MB TIF)
Figure S4 Purity of FACS isolated CD4+CD25high T-cells. (A)
Standardized sorting procedure based on gating of top 1.2%
CD25-expressing CD4+ T-cells as CD4+CD25high (Tregs). Both
CD4+CD25- and CD4+CD25high cell subsets were checked for
CD127 expression. Most of CD4+CD25high T-cells do not
express CD127 (80.5%) and most of CD4+CD25- -T-cells do
express CD127 (87.1%). This is representative of 4 samples. (B)
Intracellular staining for FOXP3 in CD4+CD25- and
CD4+CD25high T-cells.
Found at: doi:10.1371/journal.pone.0006527.s004 (0.04 MB TIF)
Figure S5 Quality assessment of the arrays using AffyQC
package. These plots assess the overall signal quality for the arrays.
(A) Boxplots of all the pm (perfect match) intensities for 12 T1D
subjects (left) and 15 control subjects (right). (B) Density plot of the
intensities (log scale) for 12 T1D subjects (left) and 15 control
subjects (right). These plots suggest that arrays used in this study
are good quality as none of the arrays have a low average intensity
or a significantly different shaped density. (C) RNA digestion plot
for (left) 15 control subjects and (right) 12 T1D subjects. The mean
intensity of expression of all genes on each array is plotted as a
function of 59-39 position of probes. For each array and within
each probe-set, probes are arranged by their proximity to the 59
end of the gene. The plot shows the average intensity of the probes
as a function of 59-39 position of probes. Each line corresponds to
an array and the slope of its trend indicates potential RNA
degradation of the genetic material hybridized to the array.
Parallel lines indicate similar RNA degradation patterns across
arrays.
Found at: doi:10.1371/journal.pone.0006527.s005 (0.14 MB TIF)
Figure S6 Flowchart of the gene expression analysis pipeline
Found at: doi:10.1371/journal.pone.0006527.s006 (0.03 MB TIF)
Figure S7 BGX measures and estimation of differentially
expressed genes. These plots summarise the main steps of the
BGX algorithm. (A) Kernel density plots are calculated for the
expression of each gene (n=1 to 54675) in each phenotype, from
the cumulative information from all subjects within a phenotype.
(B) The corresponding plots of the posterior distribution of the
expression differences are calculated for each gene across the two
phenotypes. (C) Histogram of the posterior distribution of
expression differences. Under the null hypothesis, the histogram
of the posterior distribution of expression differences P(dg,0) will
be unimodal with a mode of 0.5 and have smoothly decreasing
T-Cell Apoptosis in T1D
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deviations from the expected shape indicate the presence of
differentially expressed genes. The black curve is the expected
distribution (by Efron’s method [79]) and the grey curve is the
observed distribution. Excess of P(dg,0) values near zero and one
indicate over-expressed and under-expressed genes in phenotype 2
(T1D subjects) relative to phenotype 1 (Control subjects),
respectively. In the final step, genes are ranked using the
standardized BGX difference (z-score) between the two conditions,
which takes into account the estimated difference in expression
level as well as the associated uncertainty.
Found at: doi:10.1371/journal.pone.0006527.s007 (0.06 MB TIF)
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